Skip to main content

Clinical Trials Center (CTC) - Promotion operation support (CTSU)

Promotion means operations support to clinical studies sponsorship activities.

CTC is a support service, taking into account aspects of commercial and academic clinical research, with the mission of providing professional assistance to clinical research by centralizing and harmonizing the administrative, operational (eg: data management, monitoring), contractual and financial management of clinical studies.

Wihtin the CTC, the Clinical Trials Support Unit (CTSU) is an operational support unit for academic clinical research into all types of cancer. Certain scientific questions of interest to patients can only be understood by means of academic research. This academic research must comply with all quality standards and legal and regulatory requirements applicable to research. It must also be carried out efficiently. 

It is for all these reasons that the Institut Bordet, in a desire to develop and encourage such research, decided to create the CTSU. This unit within the Institution brings together the skills and resources needed to conduct high-level research. The CTSU team is responsible for responding to research questions and evaluating the benefits and risks of drugs and procedures, while always ensuring that the patients participating in the clinical studies are adequately protected.

Our team

Director of Research Administration
Marielle Sautois

Deputy Director of Research Administration & Head of CTSU Operations
Julie Gaye

Associate Head of CTSU Operations & Quality Manager
Magalie Krieguer

CDIT Team Leader
David Lerens

Project Manager Senior
Diane Delaroche

Regulatory Affairs Manager
Frédéric Hénot

Pharmacovigilance Manager
Marie-Pierre Gauthier

CRA Manager
Sophie Jamin

Data Manager Senior
Vanessa Honvault


 Scientific publications

Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.

Authors : Woff E, Salvatore L, Marmorino F, Genovesi D, Critchi G, Guiot T, Ameye L, Sclafani F, Hendlisz A, Flamen P
Year : 2022
Journal : J Nucl Med
Volume : 63
Pages : 549-555

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 38

Genomics of metastatic breast cancer

Authors : Geukens T, De Schepper M, Richard F, Maetens M, Van Baelen K, Leduc S, Isnaldi E, Nguyen HL, Bachir I, Vandenberghe E, Van den Bogaert W, Punie K, Neven P, Wildiers H, Floris G, Desmedt C
Year : 2022
Journal : Belgian J Medical Oncology
Volume : 16(1)
Pages : 18-28

Radiomics software comparison using digital phantom and patient data: IBSI-compliance does not guarantee concordance of feature values.

Authors : Paquier Z, Chao SL, Acquisto A, Fenton C, Guiot T, Dhont J, Levillain H, Gulyban A, Bali MA, Reynaert N
Year : 2022
Journal : Biomed Phys Eng Express
Volume : 8

The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer.

Authors : Isnaldi E, Richard F, De Schepper M, Leduc S, Maetens M, Geukens T, Van Baelen K, Nguyen HL, Rouas G, Zoppoli G, Cardoso F, Sotiriou C, Larsimont D, Floris G, Biganzoli E, Desmedt C
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 90